Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

about

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

Item

http://www.wikidata.org/entity/Q51539386

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

@en

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

@nl

type

Item

label

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

@en

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

@nl

prefLabel

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

@en

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

@nl

P1476

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines

@en

P2093

Michael R Batzloff

http://www.w3.org/2001/XMLSchema#string

Saranya Chandrudu

http://www.w3.org/2001/XMLSchema#string

Waleed M Hussein

http://www.w3.org/2001/XMLSchema#string

P2860

Streptococcal M protein: molecular design and biological behavior.

The global burden of group A streptococcal diseases.

Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.

Recent progress in adjuvant discovery for peptide-based subunit vaccines

Group a streptococcal diseases and their global burden.

Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice.

Pathogenesis of group A streptococcal infections and their sequelae.

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

More than one reason to rethink the use of peptides in vaccine design.

P304

601-609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/TDE-2016-0037

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27582233

http://www.w3.org/2001/XMLSchema#string